This compound is a synthetic peptide pharmaceutical raw material designed as an LHRH agonist. It consists of a decapeptide chain with multiple amino acid residues and is supplied as an acetate salt form suitable for research and pharmaceutical manufacturing.
Escopo do conteúdo: As informações desta página dizem respeito à identificação química e aos contextos de fornecimento industrial, pesquisa e produção. Não constituem alegação terapêutica, aconselhamento médico ou instruções de uso de medicamentos.
Adquirindo ou fornecendo este composto?
Publique seu inventário ou uma solicitação de compra
CAS 1426174-33-5
(-)-Pantoprazole
active pharmaceutical ingredient
((1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-1-hydroxy-15-((2R,3S)-2-hydroxy-3-((2-methylpropan-2-yl)oxycarbonylamino)-3-phenylpropanoyl)oxy-9,12-dimethoxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo(11.3.1.03,10.04,7)heptadec-13-en-2-yl) benzoate;propan-2-one
active pharmaceutical ingredient
Carbidopa
active pharmaceutical ingredient
Dihydro-alpha-ergocryptine mesylate
active pharmaceutical ingredient
(Des-Gly10,D-His2,D-Ser(tBu)6,Pro-NHEt9)-LHRH Acetate
n.a
[1-(5-oxo-D-proline)]buserelin
active pharmaceutical ingredient
Buserelin EP Impurity B
Active pharmaceutical ingredient reference standard
Buserelina
GnRH agonist therapeutic peptide
acetic acid;(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
PYMDEDHDQYLBRT-OODYQVIQSA-N
CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6.CC(=O)O